Seminars in Pediatric Neurology, published by W B SAUNDERS CO-ELSEVIER INC, is a prestigious journal dedicated to the evolving field of pediatric neurological disorders. Since its inception in 1994, this peer-reviewed journal has provided critical insights and cutting-edge research to support healthcare professionals in enhancing the quality of care for children with neurological conditions. With an impressive 2023 impact factor and a Q2 ranking in both the clinical neurology and pediatrics categories, it stands as a vital resource, fostering the dissemination of knowledge among researchers and clinicians alike. Featuring articles that explore a range of topics from clinical trials to innovative treatment modalities, this journal empowers practitioners with the latest findings in pediatric neurology. While primarily subscription-based, it plays a key role in bridging the gap between academia and clinical practice, making it an indispensable tool for anyone involved in the care and treatment of pediatric neurological patients.

Therapeutic Advances in Neurological Disorders, published by SAGE Publications Ltd, is a leading open access journal dedicated to the advancement of knowledge in the field of neurology. Since its inception in 2008, this journal has established itself as a vital resource for researchers, healthcare professionals, and students, offering a platform for the dissemination of high-quality research that improves the understanding and treatment of neurological disorders. With a commendable impact factor and ranked Q1 in multiple categories, including Neurology and Pharmacology for 2023, it exemplifies excellence in scholarly contributions. The journal's Scope encompasses a wide array of topics, providing insights that are pivotal for clinical practice and pharmacological development. Additionally, with its commitment to open access since 2017, Therapeutic Advances in Neurological Disorders ensures that its research reaches a global audience, fostering collaboration and innovation in neurological science.

Progress in Neurology and Psychiatry is a pivotal journal published by John Wiley & Sons Ltd, dedicated to advancing the fields of neurology and psychiatry. With a robust history dating back to its establishment, this esteemed journal holds a consistent Q3 ranking in 2023 across several categories including Neurology, Clinical Neurology, Psychiatry, and Mental Health, signifying its significant contribution to the scientific community. This journal serves as a vital source of knowledge and insight, publishing original research, reviews, and case studies that explore the intricacies of neurological and psychiatric disorders. Although it does not offer open access, the journal remains accessible to a wide audience through institutional subscriptions. By fostering a platform for scholarly discourse, Progress in Neurology and Psychiatry aims to bridge the gap between research and practice, ultimately enhancing the quality of care for individuals with neurological and psychiatric conditions. Researchers, clinicians, and students are encouraged to engage with the journal's comprehensive content to stay informed of the latest developments and emerging trends in these critical fields of medicine.

CLINICAL NEUROPHARMACOLOGY, published by Lippincott Williams & Wilkins, stands as a premier journal dedicated to advancing the understanding of pharmacological interventions in the realm of neurology. With its ISSN 0362-5664 and E-ISSN 1537-162X, this journal has been a vital resource since its inception in 1982, consistently contributing valuable research and reviews to the fields of clinical neurology and pharmacology. As reflected in its 2023 Quartile Ranking of Q3 in neuroscience and pharmacological categories, CLINICAL NEUROPHARMACOLOGY plays a crucial role in disseminating knowledge among researchers and clinicians alike, showcasing innovative studies that enhance therapeutic practices. The journal promotes rigorous peer-reviewed scholarship and emphasizes access to cutting-edge findings, making it an essential read for professionals aiming to bridge the gap between research and clinical application. Although it operates on a subscription model, the depth and quality of research it presents ensure its significance and utility in advancing the science of neurological pharmacotherapy. For anyone invested in the synergy of pharmacology and neurology, CLINICAL NEUROPHARMACOLOGY is the premier destination for insightful and impactful scholarly communication.

EXPERT OPINION ON PHARMACOTHERAPY, published by Taylor & Francis Ltd, stands as a vital resource in the fields of medicine and pharmacology, consistently recognized for its significant contributions to both disciplines. With an impressive impact factor, this journal ranks in the second quartile (Q2) across several key categories, including Medicine (miscellaneous), Pharmacology, and Medical Pharmacology, underscoring its influence within the academic community. Since its inception in 1999, the journal has provided a platform for peer-reviewed articles that critically evaluate emerging therapies and innovative pharmacological approaches, making it essential reading for researchers, healthcare professionals, and students alike. Although it operates under a subscription model, its comprehensive coverage of pharmacotherapeutic developments ensures that it remains a cornerstone for those seeking new insights and expert analyses in the rapidly evolving landscape of drug therapy.

SEMINARS IN NEUROLOGY is a leading journal in the field of neurology, published by THIEME MEDICAL PUBL INC. With its ISSN 0271-8235 and E-ISSN 1098-9021, this esteemed journal has been a vital resource for the neurology community since its inception in 1984. Covering critical advancements and contemporary issues in both neurology and clinical neurology, it holds a reputable position in the Q2 category for both disciplines as of 2023. The journal ranks #164 out of 400 in clinical neurology, indicating its significant contribution to the field, and is indexed in Scopus for robust academic exposure. SEMINARS IN NEUROLOGY offers a platform for authors to disseminate groundbreaking research and reviews, ultimately enhancing knowledge and practice in neurological sciences. With unrestricted access options, it seeks to engage researchers, practitioners, and students, fostering a comprehensive understanding of the complexities of neurological disorders and therapies.

Neuropsychiatric Disease and Treatment, published by DOVE MEDICAL PRESS LTD, is a prominent open access journal dedicated to advancing the field of neuropsychiatry. Since its inception in 2009, this journal has provided a platform for the dissemination of high-quality research on innovative therapies and treatments for neuropsychiatric disorders. With an impressive Q2 ranking in Psychiatry and Mental Health and a Q3 ranking in Biological Psychiatry as of 2023, it holds a reputable position within the scholarly community, reflecting its commitment to impactful research. The journal's open access model ensures widespread accessibility, fostering collaboration and dialogue among researchers, clinicians, and students worldwide. The journal accepts a variety of article types, including original research, reviews, and case studies, encompassing a range of topics from pathophysiology to therapeutic advancements. With its base in New Zealand and a Scopus rank placing it within the 69th percentile of Psychiatry and Mental Health, Neuropsychiatric Disease and Treatment is an essential resource for those dedicated to understanding and treating the complexities of neuropsychiatric conditions.

EXPERT OPINION ON BIOLOGICAL THERAPY, published by Taylor & Francis Ltd, is a prestigious journal that has been a cornerstone in the fields of Clinical Biochemistry, Drug Discovery, and Pharmacology since its inception in 2001. With an impressive impact factor reflecting Q1 status across its categories in 2023, this journal is ranked among the top in both the pharmacology and biochemistry domains, featuring in the 81st and 77th percentiles respectively. This makes it an essential resource for researchers, professionals, and students who are keen on staying at the forefront of biological therapy advancements. The journal encompasses a broad yet focused scope, providing valuable insights into innovative therapeutic strategies and drug development methodologies. Researchers benefit from the rigorous peer-review process and the opportunity to disseminate their findings to a global audience, without the constraints of open access, ensuring the integrity and prestige of published work. As it converges towards 2024, EXPERT OPINION ON BIOLOGICAL THERAPY remains an influential platform for fostering collaboration and discussion in the evolutionary landscape of biological therapies.

The JOURNAL OF CHILD NEUROLOGY is a distinguished publication in the critical fields of neurology and pediatrics, published by SAGE PUBLICATIONS INC. With its ISSN 0883-0738 and E-ISSN 1708-8283, this journal has been a pivotal resource since its inception in 1986, serving the needs of researchers, clinicians, and students dedicated to advancing the understanding and treatment of neurological disorders in children. As evidenced by its impressive Q2 rankings in both Neurology (clinical) and Pediatrics, Perinatology, and Child Health, the journal has established a reputable position within the academic community, ranking in the 75th percentile for pediatrics and the 53rd percentile for clinical neurology. This periodical not only contributes to the body of knowledge in child neurology but also promotes interdisciplinary collaboration, engaging a global audience through innovative research articles and case studies. Although the journal is not open access, it remains committed to disseminating high-quality research aimed at improving pediatric health outcomes, making it an essential read for professionals and researchers dedicated to this crucial area of medicine.

FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE is a pivotal journal in the fields of neurology, psychiatry, and related medical disciplines, published by GEORG THIEME VERLAG KG in Germany. With a history dating back to 1955, this journal has evolved to address the dynamic nature of neurological and psychiatric research, offering valuable insights and advancements in the field. Despite holding a Q4 category status in various medical domains according to the 2023 quartiles, the journal continues to foster academic discussion and engagement among researchers and clinicians alike. It serves as a vital platform for disseminating knowledge through original research articles, reviews, and clinical studies, making it an essential resource for professionals and students aiming to stay abreast of the latest developments in mental health and neurological science. Although the journal currently does not offer open access options, its contribution to the academic community is significant, helping to illuminate the intricate relationships between neurological disorders and psychiatric conditions.